ClinicalTrials.gg
RecruitingNCT07106970Updated Oct 26, 2026

PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II)

An interventional study of Linear ablation and PVI alone in Persistent Atrial Fibrillation, sponsored by Boston Scientific Corporation. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Boston Scientific Corporation · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
640
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 73 studies in Atrial Fibrillation by Boston Scientific Corporation — 8 open to participants now, 20 under way, none of them phase 3. Atrial Fibrillation · Boston Scientific Corporation.

Planned enrollment
10th of 51
640 · median 200
Started
2025
with 8 others
No phase
45 of 73
8 open now
Primary completion
2027-12
later than 11 of 19 live
Registered
65th of 73
by date

Among the 73 studies in Atrial Fibrillation by Boston Scientific Corporation, this one is the 10th largest by planned enrollment of the 51 interventional ones that give a count, is one of 9 that started in 2025, is one of 45 with no phase, reaches primary completion later than 11 of the 19 other live ones, and was the 65th registered.

Atrial Fibrillation

4,016 studies on the registry are indexed under Atrial Fibrillation; 963 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

8 of the 73 studies in Atrial Fibrillation by Boston Scientific Corporation are open now, in 11 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 609 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Atrial Fibrillation by Boston Scientific Corporation, or all of them as a file.
02

Study summary

This study is a prospective, multicenter, open-label, randomized controlled trial to investigate whether a linear ablation in addition to pulmonary vein isolation (PVI) outperforms PVI alone using pulsed field ablation (PFA) in maintaining sinus rhythm for persistent atrial fibrillation (PerAF)

Read the detailed description

This study is a prospective, multicenter, open-label, randomized controlled trial to investigate whether a linear ablation in addition to PVI outperforms PVI alone using PFA in maintaining sinus rhythm for PerAF. Enrolled subjects will be randomized by the ratio of 1:1 into PVI and linear ablation arm or PVI alone arm. Subjects in PVI and linear ablation arm will undergo bilateral PVI, and linear ablations in the posterior wall (PW), mitral isthmus (MI) and cavo-tricuspid isthmus (CTI) using the study device and EIVOM could be performed additionally before or after PFA at the operator's discretion, it is recommended to perform EIVOM first. Subjects randomized to the PVI alone arm will undergo PVI only. If atrial fibrillation (AF) cannot be terminated during ablation, cardioversion will be performed. After ablation, all the subjects will be followed at discharge, 1 month and then at 3-month intervals up to 12 months.

03

Conditions studied

  • Persistent Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Study subjects are required to meet all the following inclusion criteria:

  1. Subjects with an age range of 18 years or above and 80 years or below.
  2. Subjects have symptomatic, drug-resistant, persistent AF, defined as:

    1. Symptomatic: these symptoms include but not limited to palpitations, presyncope, syncope, fatigue, and shortness of breath.
    2. Drug-resistant: effectiveness failure of, intolerance to, or specific to at least one AAD.
    3. Persistent: continuous AF for > 90 days, i) with a minimum a physician's note confirming the diagnosis AND,within 180 days of Enrollment Date, either a 24-hour or longer continuous recording confirming continuous AF OR Two ECGs showing continuous AF taken at least 90 days apart.
  3. Subjects undergoing a first-time ablation procedure for AF.
  4. Subjects who are willing and capable of providing ICF and participating in all testing associated with this study.

Exclusion criteria

Exclusion Criteria:

  1. AF that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible/non-cardiac causes.
  2. Left atrial anteroposterior diameter ≥ 6.0 cm by transthoracic echocardiography (TTE) within 3 months prior the procedure.
  3. Heart failure with (LVEF) \< 30% by TTE within 3 months prior the procedure.
  4. LA thrombus detected by Transesophageal Echocardiography (TEE) or cardiac CT within one day before the procedure or Intracardiac Echocardiography (ICE) before atrial septal puncture during the procedure.
  5. Current or anticipated pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy devices, mechanical valve, interatrial baffle, closure device, patch, or patent foramen oval occlude, left atrial appendage closure at the time of ablation.
  6. Any of the following events within 90 days of the Consent Date:

    1. Myocardial infarction, unstable angina or coronary intervention or any cardiac surgery
    2. Pericarditis or symptomatic pericardial effusion
    3. Gastrointestinal bleeding
    4. Stroke, (TIA), or intracranial bleeding or any non-neurologic thromboembolic event
  7. to, or unwillingness to use systemic anticoagulation.
  8. Subjects cannot be removed from Class I/III AAD for reasons other than atrial arrhythmia.
  9. Women of who are pregnant or lactating.
  10. Renal insufficiency if an estimated (eGFR) is \< 30 mL/min/1.73 m2, or with any history of renal dialysis or renal transplant.
  11. Conditions that in the investigator's medical opinion would interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation.
  12. Predicted less than 12 months.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
640 participants (estimated)

Study arms

  • Experimental
    PVI and linear ablation arm

    Subjects in PVI and linear ablation arm will undergo bilateral PVI, and linear ablations in the posterior wall (PW), mitral isthmus (MI) and cavo-tricuspid isthmus (CTI) using the study device, and EIVOM could be performed additionally before or after PFA at the operator's discretion.

    Procedure: Linear ablation · Procedure: PVI alone

  • Active comparator
    PVI alone arm

    Subjects randomized to the PVI alone arm will undergo PVI only with the study device.

    Procedure: PVI alone

Interventions

  • ProcedureLinear ablation

    Linear ablations in the posterior wall (PW), mitral isthmus (MI) and cavo-tricuspid isthmus (CTI) using the study device.EIVOM could be performed additionally before or after PFA at the operator's discretion.

  • ProcedurePVI alone

    Undergo PVI with the study device

06

What researchers measure

Primary outcomes

  1. Primary Effectiveness Endpoint with Treatment Success.

    Number of Participants free from Arrhythmia, Re-ablation, Cardioversion, and AAD use.

    Time frame: Completion of treatment 360 days compared with the baseline

  2. Primary Safety Endpoint with Safety events related to AF catheter ablation.

    Number of Participants with following device or procedure-related serious Composite Adverse Events (CAEs).

    Time frame: Completion of treatment 360 days compared with the baseline

Secondary outcomes

  1. Secondary Effectiveness Endpoint with Chronic Success.

    Number of Participants with Chronic Success, Freedom from any documented AF, AFL or AT episode lasting ≥10s via 12-lead ECG or ≥30s via Holter (or other continuous rhythm monitoring device) on/off AADs after the blanking period to Day 360.

    Time frame: Completion of treatment 360 days compared with the baseline.

  2. Secondary Safety Endpoint with Non-SAE.

    Number of Participants with Non-Serious Composite Adverse Event

    Time frame: Completion of treatment 360 days compared with the baseline

07

Study locations

1 of 1 sites recruiting
  • Beijing Anzhen Hospital, affiliated to Capital Medical University
    Beijing, 101118, China
    Recruiting
    • Caihua Sang, Doctor · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 28 months is above that.

Counting every sponsor, half of 1,049 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Aug 6, 2025
StartActual
Aug 28, 2025
Primary completionEst.
Dec 30, 2027
CompletionEst.
Aug 30, 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Oct 26, 2026
Show all 2 updates
  1. Oct 26, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 29, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07106970
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Aug 28, 2025
Primary completion
Dec 30, 2027 (estimated)
Completion
Aug 30, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Taimin Yue
Contact
taimin.yue@bsci.com
86-10-8574 2988
Changsheng Ma, Doctor
principal investigator · Beijing Anzhen Hospital of the Capital University of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion